What ARBORMED does

ARBORMED Co., Ltd. (주식회사 아보메드) is a privately held South Korean biopharmaceutical company founded in 2017 and headquartered in Pangyo, Seongnam-si, with a US subsidiary (ARBORMED Pharmaceuticals Inc.) in San Francisco established in 2018. The company operates two divisions: an innovative drug pipeline targeting rare and intractable diseases, and a complex-generics commercialization arm focused on the US market. Its core technology assets include ARBM-101, a methanobactin-based copper chelator licensed from Helmholtz Zentrum München and being developed for Wilson's disease with FDA Orphan Drug Designation; ARBM-201, a first-in-class pendrin inhibitor for Acute Respiratory Distress Syndrome licensed from Yonsei University Health System; and ARBM-301, a pendrin corrector for Pendred syndrome, also from Yonsei. A fourth candidate, ARBM-401, is undisclosed. Methanobactin selectively binds copper and facilitates biliary/fecal excretion, differentiating from existing chelators (penicillamine, trientine, TTM); ARBM-201 acts by reducing pendrin expression and anion-exchange activity in alveolar epithelial cells, blocking NF-κB-driven inflammation.

ARBORMED generates revenue through three channels: (1) exclusive US distribution rights for complex generic pharmaceuticals (Sugammadex, Ferric Carboxymaltose, Calcitonin Salmon, and others) sourced from Korean and international manufacturers (Penmix, Korea United Pharmaceutical, iCure, Etico Life Sciences), filed via ANDA with the US FDA through the US subsidiary; (2) technology licensing-out of innovative candidates, most notably the December 2025 European licensing agreement with Hyloris Pharmaceuticals SA for ARBM-101 covering Wilson's disease, iron overload disorders and primary biliary cholangitis, valued at up to KRW 2.3 trillion (USD 160 million) including milestones, royalties and upfront payments; and (3) pre-IPO investment capital, with cumulative funding of approximately KRW 42.7 billion plus USD 1.6 million raised since founding, and a KOSDAQ listing targeted for 2027 via the Technology Special Exemption System.

The company serves rare-disease patients (Wilson's disease, ARDS, Pendred syndrome), US hospitals and pharmacies requiring complex generics, and pharmaceutical partners seeking US or European market access. It maintains an 18-partner ecosystem of universities, research institutes, pharma companies and CROs, and is led by Co-CEOs Kyojin Park and Weonbin Im, supported by a Chief Strategy Officer (Manish Singhal), CFO (Kangseok Yoon) and Head of Business Development (Anand Rai), with a scientific advisory network of 12 US Wilson's disease specialists led by Yale Professor Michael Schilsky.

Name

ARBORMED

Legal name

주식회사 아보메드 (Arbormed Co., Ltd.)

Website

https://arbormed.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

ARBORMED is a Korean biopharmaceutical company developing first-in-class treatments for rare diseases (Wilson's disease, ARDS, Pendred syndrome) and commercializing complex generic pharmaceuticals in the US market.

Ownership category

akta.pro rank

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Complex Generic Distribution: ARBORMED obtains exclusive US distribution rights for complex generic pharmaceuticals from Korean and international partners (Penmix, Korea United Pharmaceutical, iCure, Etico Life Sciences, etc.). The company files ANDAs with US FDA and commercializes finished drugs through its US subsidiary. Complex generics are difficult to manufacture with limited competition, ensuring profitability.
2. Technology Licensing-Out: Licensing-out agreements for innovative drug candidates to global pharmaceutical partners. Includes upfront payments, milestone payments, and royalties. European licensing agreement with Hyloris for ARBM-101 covers multiple indications (Wilson disease, iron overload disorders, PBC) with total deal value up to KRW 2.3 trillion (USD 160 million).
3. Pre-IPO Investment Capital: The company is raising Pre-IPO funding from US-based investors to finance clinical development and global business expansion. Recent USD 1.6 million investment from OIC, LLC demonstrates recognition of pipeline value in overseas markets.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

ARBORMED develops novel therapeutics for rare diseases (Wilson's disease, ARDS, Pendred syndrome) using proprietary platforms including methanobactin and pendrin-based technologies, and licenses out drug candidates to global pharmaceutical partners. The company separately commercializes complex generic injectable pharmaceuticals in the US market through exclusive distribution rights with manufacturing partners, with ANDAs filed via its US subsidiary ARBORMED Pharmaceuticals Inc.

Product overview

ARBORMED is a diversified biopharmaceutical company with two main divisions: Innovative new drug development and Complex generics. The innovative drug pipeline includes ARBM-101 (Methanobactin for Wilson's disease), ARBM-201 (Pendrin Inhibitor for ARDS), ARBM-301 (Pendrin corrector for Pendred Syndrome), and ARBM-401 (undisclosed). The Complex Generic division focuses on commercializing difficult-to-manufacture generic products with limited competition in the U.S., including Sugammadex and Ferric Carboxymaltose.

Differentiator

Problem solved

Functional benefit

Products and services

• ARBM-101 A methanobactin-based drug candidate for Wilson's disease that prevents or stops liver damage progression by facilitating copper excretion through the bile-feces pathway. Licensed to Hyloris Pharmaceuticals SA for Europe in December 2025.
• ARBM-201 A first-in-class pendrin inhibitor for Acute Respiratory Distress Syndrome (ARDS) that reduces pendrin expression and anion exchange activity in alveolar epithelial cells, blocking downstream NF-κB signaling and inflammation.
• ARBM-301 A pendrin corrector for Pendred Syndrome that rescues pendrin protein from degradation by correcting the conformation of mutated pendrin protein retained in the ER, allowing cell surface targeting.
• ARBM-401 Undisclosed drug candidate in ARBORMED's pipeline. Details of indication and mechanism are not publicly disclosed.
• Sugammadex Complex Generic A complex generic neuromuscular blockade reversal agent; ANDA submitted to U.S. FDA in February 2026 with FDA approval target end of 2026.
• Ferric Carboxymaltose Complex Generic A complex generic treatment for iron deficiency anemia with planned U.S. FDA approval application target in 2027.

Quantifiable outcome

• ARBM-101 demonstrated significantly faster copper excretion compared to control groups and all known copper chelators in Wilson's disease rat models
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

14 partnerships are on record, tiered core, flagship and minor.

• Penmix Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 1 February 2026Partnership for complex generic Sugammadex and Ferric Carboxymaltose. Penmix handles product development, manufacturing, and supply; ARBORMED handles US FDA ANDA application and commercialization (marketing/distribution). ANDA submitted for Sugammadex in February 2026 with FDA approval target end of 2026. Ferric Carboxymaltose approval targeted for 2027.
• Hyloris Pharmaceuticals SAflagshipStrategic or Co-development Partner · 1 December 2025European licensing agreement for ARBM-101 covering multiple indications including Wilson disease, iron overload disorders (hereditary hemochromatosis), and primary biliary cholangitis (PBC). Total deal value up to KRW 2.3 trillion (USD 160 million) including milestones. Hyloris handles clinical development, regulatory approval, pricing/reimbursement, and commercialization across Europe.
• Korea United Pharmaceutical (한국유나이티드제약)coreChannel Partner/ Reseller/ Distributor · 1 November 2023Exclusive US distribution rights for complex generic products. US export agreement established in 2018. Partnership for bringing Korean pharmaceutical products to US market through ARBORMED's regulatory and commercial infrastructure.
• BC World Pharm Co., Ltd.coreStrategic or Co-development Partner · 1 May 2022Research collaboration agreement signed in May 2022 for new drug development targeting acute respiratory distress syndrome (ARDS). Collaboration on ARBM-201 and related pendrin inhibitor programs.
• Ildong Pharmaceutical (일동제약)coreStrategic or Co-development Partner · 1 October 2021Joint R&D agreement signed in October 2021. SI (Strategic Investment) of KRW 6 billion as part of Series B funding. Collaboration on new drug R&D and business development. Ildong is a major Korean pharmaceutical company contributing to both capital and strategic partnership.
• Yonsei University Health SystemcoreStrategic or Co-development Partner · 1 June 2021Research collaboration agreement and technology transfer contract for ARDS and Pendred syndrome treatments. In-licensing of pendrin inhibitor (ARBM-201) and pendrin corrector (ARBM-301) technologies. This partnership provided key pipeline candidates for acute respiratory distress syndrome and congenital hearing loss.
• Helmholtz Zentrum MünchencoreTechnology or Integration · 1 March 2019In-licensing of methanobactin technology from Germany's Helmholtz Zentrum München research institute in March 2019. This provided the foundational technology for ARBM-101, a first-in-class treatment for Wilson's disease using methanobactin's unique copper-binding properties.
• iCure (아이큐어)coreChannel Partner/ Reseller/ Distributor · 1 January 2017US export agreement established in 2017. Partnership for distribution of transdermal drug delivery products and other pharmaceutical products in US market.
• University of WisconsinminorStrategic or Co-development PartnerAcademic research partner listed in company's partnership portfolio. Collaboration on scientific research and development activities.
• University of MichiganminorStrategic or Co-development PartnerAcademic research partner. Co-CEO Kyojin Park served as Business Consultant at University of Michigan Hospital International Patient Center.
• Iowa State UniversityminorStrategic or Co-development PartnerAcademic research partner listed in company's partnership portfolio.
• Yonsei University (연세대학교)coreStrategic or Co-development PartnerAcademic partner for research collaboration and technology transfer related to ARDS and Pendred syndrome treatments.
• KAISTminorStrategic or Co-development PartnerAcademic research partner listed in company's partnership portfolio for collaborative R&D activities.
• Gachon University (가천대학교)minorStrategic or Co-development PartnerAcademic research partner listed in company's partnership portfolio.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Regional players

• Daewoong Pharmaceutical: Korean pharmaceutical company with a mix of innovative pipeline programs and complex generics. Comparable as a Korean biopharma pursuing dual innovative-generics strategy and US FDA approval pathways.
• Hutchmed (China) Limited: Asia-headquartered biopharma developing innovative oncology and rare-disease therapeutics with global licensing deals. Comparable in its Asia-originated innovation model with US/EU licensing-out strategy mirroring ARBORMED's Hyloris deal.
• Ildong Pharmaceutical: Major Korean pharmaceutical company and ARBORMED strategic investor (KRW 6B SI). Comparable as a Korea-based pharma with both innovative-pipeline investments and complex-generics business; strategic-investor overlap makes it a direct functional peer.
• Dong-A ST: Mid-sized Korean pharmaceutical company where Co-CEO/CTO Weonbin Im was previously VP of Research. Comparable Korean-domestic biopharma with proprietary small-molecule pipeline and US commercialization experience (e.g., Sivextro).

Broad incumbents

• Recordati Rare Diseases: European specialty pharma group with a dedicated rare-disease business unit. Comparable end-market (orphan-disease therapeutics) and global commercial footprint relevant to ARBORMED's out-licensing and royalty strategy.
• BioMarin Pharmaceutical: Global rare-disease biotech with commercialized enzyme-replacement and gene therapies for ultra-rare conditions. Comparable therapeutic-area strategy and regulatory pathway (orphan designation, accelerated approval) as ARBORMED's pipeline candidates.
• Alexion / AstraZeneca Rare Disease: Established global leader in rare-disease therapeutics (Soliris, Strensiq). Highly comparable therapeutic-area focus to ARBORMED's rare-disease pipeline and serves as the benchmark for fully integrated rare-disease commercial economics.
• BridgeBio Pharma: US clinical-stage biotech focused on genetically defined rare diseases. Comparable to ARBORMED in its small-molecule and biologic approach to monogenic disorders, but at significantly larger scale and broader pipeline scope.

Direct peers

• Ultragenyx Pharmaceutical: Clinical-stage biotech developing novel therapies for rare and ultra-rare genetic diseases. Closely comparable in indication scope (genetic, metabolic, congenital disorders), orphan-drug regulatory strategy, and partnership-driven commercialization model.
• Hyloris Pharmaceuticals SA: Belgian specialty pharma that is ARBORMED's European licensing partner for ARBM-101. Hyloris focuses on reformulating and repurposing established molecules in rare and underserved diseases, a closely aligned business model that makes it both partner and direct strategic comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARBORMED